Ça m’avait échappé : une étude italienne (6 août 2020) sur 4408 patients traités chloroquine ou hydrochroloquine fin 2019 : aucun effet prophylactique constaté.
Susceptibility to COVID‐19 in patients treated with antimalarials : a population based study in Emilia‐Romagna, Northern Italy
▻https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.41475
Results. 4,408 patients were identified. The prevalence of antimalarial users was 0.85/1000 in males and 3.3/1000 in females. The cumulative incidence of being tested during the study period was 2.7% in the general population and 3.8% in CQ/HCQ users, while the cumulative incidence of testing positive was 0.55% in the general population and 0.70% in users. Multivariate models showed that CQ/HCQ users had a slightly higher probability of being tested compared to general population (OR 1.09, 95%CI 0.94-1.28), the same probability of being diagnosed with COVID-19 (OR 0.94, 95%CI 0.66-1.34), and a slightly lower probability of being positive once tested (OR 0.83, 95%CI 0.56-1.23). All three differences were not statistically significant.
Conclusions: Our study did not support the prophylactic use of antimalarials for COVID-19